Current and future of targeted therapies against BCR::ABL kinases. [PDF]
Jayavel S +3 more
europepmc +1 more source
Editor's Note: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1-BCR-ABL-JAK2 Complex. [PDF]
europepmc +1 more source
Clinical Significance of the S348l Mutation in BCR-ABL as a Dominant Variant in Indonesian CML Patients Under Tyrosine Kinase Inhibitor Therapy: A Cohort Study. [PDF]
Harjianti T +6 more
europepmc +1 more source
Exosome and BCR-ABL mediated molecular alterations in endothelial cells in chronic myeloid leukemia: identification of seven genes and their regulatory network. [PDF]
Shen Z +16 more
europepmc +1 more source
Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib. [PDF]
Hajjo R +4 more
europepmc +1 more source
Under ONIOM Layers: Analysis of BCR-ABL Enzyme Inhibitors Through Bond-Critical Points and Natural Orbitals. [PDF]
Rocha KML, Nascimento ÉCM, Martins JBL.
europepmc +1 more source
The silent players: Atypical <i>BCR‑ABL </i>isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review). [PDF]
Zhou X +5 more
europepmc +1 more source

